logo
#

Latest news with #Globalpharma

ICO sends Dhs1.5m worth of medicines to Kenya
ICO sends Dhs1.5m worth of medicines to Kenya

Gulf Today

time3 days ago

  • Health
  • Gulf Today

ICO sends Dhs1.5m worth of medicines to Kenya

The International Charity Organisation (ICO) has dispatched a shipment of medicines to Kenya, valued at Dhs1.5 million, as part of its ongoing efforts to strengthen healthcare and support medical systems, particularly in regions with limited access to health services. The initiative was supported by Globalpharma. Khaled Al Khaja, Secretary-General of the ICO, said the initiative continues the organisation's longstanding humanitarian role since its inception and aligns with its strategy to support areas suffering from inadequate healthcare. He emphasised the organisation's commitment to responding promptly to medical appeals and ensuring the delivery of urgent pharmaceutical supplies in coordination with its field partners. He expressed his appreciation to Globalpharma for its generous contribution and confirmed that the organisation closely coordinated with its field teams to ensure the safe delivery of the medicines, in full compliance with safety, storage and transport standards, to guarantee proper distribution to beneficiaries. Recently, the ICO provided essential food packages to 400 Muslim villages aimed at alleviating hardships of the people. The initiative covered many countries, including Mauritania, Somalia, Senegal, Indonesia, the Philippines, and Kenya, delivering vital food supplies to underprivileged families for their iftar meals. Al Khaja emphasised that this effort is part of a larger plan to reach 2,000 Muslim villages. It is being carried out through the organisation's offices worldwide, based on field visits to identify the most vulnerable communities facing severe challenges. Al Khaja expressed gratitude to donors, partner organisations, and media outlets for their crucial support. The organisation has also extended significant aid to Gaza through 'Operation Chivalrous Knight 3' and continues to support vulnerable families and orphans within the UAE. The ICO has also launched 80 charitable projects in Mauritania, totalling Dhs13 million. The launch took place during a field visit by the delegation to several villages in Mauritania recently, which aims to provide large-scale aid to the most vulnerable communities. Dr. Al Khaja emphasised that the visit reflects the organisation's commitment to continuing humanitarian support for remote villages. He noted that the projects include food parcels, water distribution, orphan sponsorship, healthcare improvements, educational support, mosque construction, and zakat distribution, among others. WAM

UAE charity sends medicines worth AED 1.5 million to Kenya
UAE charity sends medicines worth AED 1.5 million to Kenya

Dubai Eye

time4 days ago

  • Health
  • Dubai Eye

UAE charity sends medicines worth AED 1.5 million to Kenya

The International Charity Organisation has dispatched a shipment of medicines, valued at AED1.5 million, to Kenya as part of its ongoing efforts to support remote areas facing limited healthcare services. The initiative was supported by Globalpharma, the national news agency Wam reported on Saturday. Khaled Al Khaja, Secretary-General of the International Charity Organisation, said the initiative ensures the delivery of pharmaceutical supplies in coordination with its field partners. He added that the teams work with ground staff to ensure the medicines are packaged well and delivered safely to those in need.

UAE charity sends medicines worth AED 1.5 million to Kenya
UAE charity sends medicines worth AED 1.5 million to Kenya

ARN News Center

time4 days ago

  • Health
  • ARN News Center

UAE charity sends medicines worth AED 1.5 million to Kenya

The International Charity Organisation has dispatched a shipment of medicines, valued at AED1.5 million, to Kenya as part of its ongoing efforts to support remote areas facing limited healthcare services. The initiative was supported by Globalpharma, the national news agency Wam reported on Saturday. Khaled Al Khaja, Secretary-General of the International Charity Organisation, said the initiative ensures the delivery of pharmaceutical supplies in coordination with its field partners. He added that the teams work with ground staff to ensure the medicines are packaged well and delivered safely to those in need.

UAE charity sends medicines worth AED 1.5 million to Kenya
UAE charity sends medicines worth AED 1.5 million to Kenya

TAG 91.1

time4 days ago

  • Health
  • TAG 91.1

UAE charity sends medicines worth AED 1.5 million to Kenya

The International Charity Organisation has dispatched a shipment of medicines, valued at AED1.5 million, to Kenya as part of its ongoing efforts to support remote areas facing limited healthcare services. The initiative was supported by Globalpharma, the national news agency Wam reported on Saturday. Khaled Al Khaja, Secretary-General of the International Charity Organisation, said the initiative ensures the delivery of urgent pharmaceutical supplies in coordination with its field partners. He added that the charity works closely with its teams on the ground to ensure the safe delivery of the medicines to guarantee proper distribution to those in need.

Globalpharma inks 4 strategic MoUs during ‘Make it in the Emirates 2025'
Globalpharma inks 4 strategic MoUs during ‘Make it in the Emirates 2025'

Zawya

time22-05-2025

  • Business
  • Zawya

Globalpharma inks 4 strategic MoUs during ‘Make it in the Emirates 2025'

'These partnerships are enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions' - Dr. Thani Al Zeyoudi Abu Dhabi, UAE – Globalpharma, the UAE's leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has signed 4 strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. The agreements reinforce the UAE's position as a regional hub for pharmaceutical innovation, localization, and advanced healthcare manufacturing. The MoUs were signed individually with each partner, reflecting Globalpharma's tailored approach to strategic collaboration. The agreements were concluded with four international players — PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada). His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment witnessed the signing ceremonies with PharmaPrimes Laboratories, Nerhadou International, and Aora Health. These partnerships span critical areas such as technology transfer, product licensing, supply, and local manufacturing. Aligned with the UAE's industrial strategy, the collaborations aim to bolster domestic production, reduce reliance on imports, and accelerate access to next-generation healthcare solutions across the region. 'The strategic collaborations announced by Globalpharma during 'Make it in the Emirates' reflect the UAE's commitment to strengthening domestic pharmaceutical manufacturing and reducing reliance on imports. These partnerships embody the core goals of the 'Make it in the Emirates' initiative—empowering local industry, accelerating innovation, and enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions,' stated His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment. "Dubai Investments' long-term strategy is rooted in enabling sectors that drive national progress, and healthcare is central to that vision. These strategic partnerships by Globalpharma reflect the commitment to advancing the UAE's industrial capabilities, promoting knowledge transfer, and building a resilient pharmaceutical ecosystem that supports regional health security and innovation-driven growth," said Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma. Among the signings, PharmaPrimes Laboratories, a leading CRO based in Amman, Jordan, has signed a strategic partnership with Globalpharma to establish advanced local capabilities for batch release and analysis of biosimilar drugs in the United Arab Emirates. This partnership reflects PharmaPrimes' commitment to strengthening quality infrastructure and providing high-quality, cost-competitive biosimilar therapies across the GCC countries, enhancing the competitiveness of the pharmaceutical sector and improving healthcare quality in the region. In another major agreement, Nerhadou International, one of Egypt's foremost nutraceutical companies, joined forces with Globalpharma to introduce a portfolio of innovative nutraceutical and over the counter (OTC) products tailored to regional health needs. The collaboration is expected to reinforce the UAE's wellness landscape by promoting preventive care and healthier lifestyles. Further expanding its footprint in the wellness space, Globalpharma entered a collaboration with Aora Health, a Spanish company known for its science-driven approach to functional supplements. The partnership will see the co-development and local manufacturing of a premium range of preventive health supplements, enabling quicker market access to European-quality wellness products across the UAE and the MENA region. Rounding out the series of partnerships, Globalpharma signed a Licensing and Supply Agreement with BioSyent Pharma Inc, a specialty pharmaceutical company committed to improving the lives of patients with unique and effective products in Canada and select international markets. The agreement covers the introduction of FeraMAX®, a patented oral iron supplement known for its high bioavailability and reduced gastrointestinal side effects. Globalpharma will undertake secondary packaging and marketing of the product within the UAE. About Globalpharma Globalpharma is a wholly owned subsidiary of Dubai Investments PJSC. Established in 1998, Globalpharma is currently a market leader in key generic pharma segments with a strong regional footprint. Globalpharma started its operations in the UAE in 2003 and expanded its growth in 2008 with product line extensions and new product launches across 14 countries in the GCC and select African markets. Currently Globalpharma has two Manufacturing plants, A state of the art Beta-Lactam Penicillin Manufacturing plant providing the Amoxicillin & AmoxiClav brands in the larger MENA region. Additionally, catering to the Lifestyle disease segments, is a General Medicine Manufacturing Plant with a variety of Liquid & Oral Solid Dose capabilities. About PharmaPrimes Laboratories PharmaPrimes Laboratories is a CRO company offering comprehensive services in drug development and delivery systems, with a strong focus on innovation and delivering effective, high-quality therapeutic solutions in the Middle East and selected global markets. Its services include Research & Development, Pharmaceutical Quality Control, Biosimilar Testing and Analysis, and Bioanalysis and Bioequivalence Studies. PharmaPrimes is committed to the highest standards of quality and international regulations to ensure reliable and efficient service delivery. About Nerhadou International Established in 1996, Nerhadou International is a leading Egyptian pharmaceutical and nutraceutical manufacturer headquartered in 6th of October City, Giza. The company pioneer's innovative healthcare solutions, including oral dispersible film (ODF) technology, and is ranked among Egypt's top 50 pharmaceutical companies for six consecutive years. With a strong presence across the Middle East and Africa, Nerhadou is committed to delivering high-quality, affordable products that enhance health and well-being. About Aora Health Aora Health is a Spain-based nutraceutical company focused on science-backed, condition-specific supplements. With a strong emphasis on research and innovation, Aora delivers high-quality products across key health segments, including digestive, cognitive, and women's health. About BioSyent Pharma Inc BioSyent Pharma Inc is a Canadian specialty pharmaceutical company dedicated to enhancing patient outcomes through innovative, in-licensed healthcare products. With a diverse portfolio spanning therapeutic areas such as iron deficiency, pain management, women's health, and oncology support, BioSyent delivers clinically proven solutions to patients and healthcare professionals across Canada and select international markets. The company is publicly traded on the TSX Venture Exchange under the symbol 'RX'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store